Gilead Sciences, Inc (NASDAQ: GILD) kicked off on Friday, up 3.01% from the previous trading day, before settling in for the closing price of $121.26. Over the past 52 weeks, GILD has traded in a range of $90.82-$128.70.
Healthcare Sector giant saw their annual sales slid by -38.13% over the last five years. While this was happening, its average annual earnings per share was recorded 76.43%. With a float of $1.24 billion, this company’s outstanding shares have now reached $1.24 billion.
Gilead Sciences, Inc (GILD) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – General Industry. The insider ownership of Gilead Sciences, Inc is 0.21%, while institutional ownership is 88.06%. The most recent insider transaction that took place on Jan 15 ’26, was worth 372,930. In this transaction Chief Financial Officer of this company sold 3,000 shares at a rate of $124.31, taking the stock ownership to the 150,503 shares. Before that another transaction happened on Jan 15 ’26, when Company’s Chief Commercial Officer sold 3,000 for $124.31, making the entire transaction worth $372,930. This insider now owns 103,221 shares in total.
Gilead Sciences, Inc (GILD) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported 1.9 earnings per share (EPS), higher than consensus estimate (set at 1.7) by 0.2. Wall Street market experts anticipate that the next fiscal year will bring earnings of 2.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 76.43% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 26.27% during the next five years compared to -38.13% drop over the previous five years of trading.
Gilead Sciences, Inc (NASDAQ: GILD) Trading Performance Indicators
Take a look at Gilead Sciences, Inc’s (GILD) current performance indicators. Last quarter, stock had a quick ratio of 1.31. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.33. Likewise, its price to free cash flow for the trailing twelve months is 16.91.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 6.46, a number that is poised to hit 1.85 in the next quarter and is forecasted to reach 8.77 in one year’s time.
